Cost of Revenue Comparison: Alkermes plc vs Travere Therapeutics, Inc.

Cost of Revenue: A Tale of Two Biopharma Companies

In the dynamic world of biopharmaceuticals, understanding cost structures is crucial for investors and stakeholders. This chart offers a decade-long comparison of the cost of revenue between Alkermes plc and Travere Therapeutics, Inc., two prominent players in the industry.

Alkermes plc: A Steady Climb

From 2014 to 2023, Alkermes plc has seen a significant fluctuation in its cost of revenue. Starting at approximately $448 million in 2014, it peaked at around $693 million in 2019, before dropping to $218 million in 2022. This represents a 51% decrease from its peak, highlighting potential strategic shifts or operational efficiencies.

Travere Therapeutics, Inc.: A Gradual Rise

Conversely, Travere Therapeutics, Inc. has experienced a steady increase in its cost of revenue, from just $571,000 in 2014 to $11.45 million in 2023. This growth, nearly 20 times the initial figure, reflects the company's expansion and increased market activities.

This comparative analysis underscores the diverse financial trajectories within the biopharma sector, offering insights into each company's operational strategies over the past decade.